

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+2.59%
-1.17%
+0.23%
REGN
Regeneron Pharma
$577.95
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
Chart
$560.75 (+3.07%)
$558.87 (+3.41%)
$484.93 (+19.18%)
$824.48 (-29.90%)
REGN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

REGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
REGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
REGN Street view is bullish but have mixed views on the near-term outlook
Average key support and resistance price levels.
Login to displayNVS
130.36
-0.97%
SNY
51.64
+4.28%
MRK
87.49
+0.36%
AZN
83.29
-0.13%
VRNA
88.00
+6.02%
What is REGN current stock price?
What are REGN stock strengths?
What risks are associated with REGN stock?
When is REGN next earnings report?
What is REGN market cap and volume?
What is REGN's current Stock IQ?
Should I buy REGN stock right now?
Is REGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for REGN?
What does a 'Strong Sell' rating mean for REGN?
What factors influence REGN's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+2.59%
-1.17%
+0.23%
REGN
Regeneron Pharma
Current Price
$577.95
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
Linked to REGN
NVS
130.36
-0.97%
SNY
51.64
+4.28%
MRK
87.49
+0.36%
AZN
83.29
-0.13%
VRNA
88.00
+6.02%
Chart
$560.75 (+3.07%)
$558.87 (+3.41%)
$484.93 (+19.18%)
$824.48 (-29.90%)
REGN Analysts Opinion
REGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
REGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
REGN Street view is bullish but have mixed views on the near-term outlook
REGN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Average key support and resistance price levels.
REGN Latest Analysis
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?. Regenerons Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Fri Oct 24, 2025
Canaccord Genuity Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation. Fintel reports that on October 23 2025 Canaccord Genuity maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Buy recommendation. Analyst Price Forecast Suggests 29.33% Upside
Fri Oct 24, 2025
Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings Beyond Revenue and EPS. Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025 looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Thu Oct 23, 2025
Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight. The emphysema market is anticipated to grow steadily fueled by a range of emerging therapies under development. Leading candidates like SAR447537 (Sanofi) Alvelestat (Mereo BioPharma) BEAM-302 (Beam Therapeutics) itepekimab (Regeneron Pharmaceuticals/Sanofi) depemokimab (GSK) and...
Tue Oct 21, 2025
Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline. Regeneron (REGN) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tue Oct 21, 2025
Heres How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today. Regeneron Pharmaceuticals (NASDAQ:) has outperformed the market over the past 20 years by 12.6% on an annualized basis producing an average annual return of 21.67%. Currently Regeneron Pharmaceuticals has a market capitalization of $62.41 billion.
Mon Oct 20, 2025
Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav
Mon Oct 20, 2025
Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav
Fri Oct 17, 2025
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised). Regenerons DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants with durable and meaningful improvements.
Thu Oct 16, 2025
REGN Factor-Based Stock Analysis - Benjamin Graham. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav
Wed Oct 15, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
REGN Stock trends
REGN Stock performance
REGN Stock analysis
REGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.